NovoCure Past Earnings Performance

Past criteria checks 0/6

NovoCure's earnings have been declining at an average annual rate of -57.4%, while the Medical Equipment industry saw earnings growing at 8.3% annually. Revenues have been growing at an average rate of 6.9% per year.

Key information

-57.4%

Earnings growth rate

-56.7%

EPS growth rate

Medical Equipment Industry Growth12.3%
Revenue growth rate6.9%
Return on equity-41.5%
Net Margin-25.9%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How NovoCure makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

BOVESPA:N2VC34 Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24578-150382210
30 Jun 24550-169382212
31 Mar 24526-193387213
31 Dec 23509-207387221
30 Sep 23504-197380224
30 Jun 23508-174354222
31 Mar 23522-141331224
31 Dec 22538-93306206
30 Sep 22543-82289208
30 Jun 22545-68279204
31 Mar 22538-59269198
31 Dec 21535-58263201
30 Sep 21546-27253188
30 Jun 21545-5246173
31 Mar 2152712232153
31 Dec 2049420225132
30 Sep 2045019216112
30 Jun 204091220698
31 Mar 20380919787
31 Dec 19351-718579
30 Sep 19322-2717470
30 Jun 19294-4116665
31 Mar 19269-5515857
31 Dec 18248-6415151
30 Sep 18232-5914346
30 Jun 18217-5913742
31 Mar 18194-6413140
31 Dec 17177-6212338
30 Sep 17154-7311537
30 Jun 17125-9511237
31 Mar 17105-11410839
31 Dec 1683-13210741
30 Sep 1665-14310844
30 Jun 1652-1359644
31 Mar 1641-1248545
31 Dec 1533-1127344
30 Sep 1525-1026044
30 Jun 1520-945343
31 Mar 1518-864941
31 Dec 1415-814540
31 Dec 1310-773335

Quality Earnings: N2VC34 is currently unprofitable.

Growing Profit Margin: N2VC34 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: N2VC34 is unprofitable, and losses have increased over the past 5 years at a rate of 57.4% per year.

Accelerating Growth: Unable to compare N2VC34's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: N2VC34 is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (1.9%).


Return on Equity

High ROE: N2VC34 has a negative Return on Equity (-41.52%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 12:20
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

NovoCure Limited is covered by 15 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Difei YangAegis Capital Corporation
Gregory GilbertDeutsche Bank
Vijay KumarEvercore ISI